AstraZeneca: Diabetes Drug Helps Prevent Kidney Complications
June 10 2019 - 1:35AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Monday that a phase 3 study of
diabetes medication Farxiga showed the drug lowered the risk of
kidney-function decline.
The data from the Declare-Timi 58 trial showed that patients
with type-2 diabetes administered Farxiga showed a 47% reduction in
the relative risk of the composite renal-specific outcome of kidney
function decline--a measure of how well the kidney filters the
blood--when compared with placebo.
Joris Silon, senior vice president of AstraZeneca's
cardiovascular, renal and metabolism unit, said the data continues
to support the consistent cardio-renal results demonstrated by
Farxiga, across a large and broad everyday patient population.
The clinical trial first reported headline results in
November.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
June 10, 2019 01:20 ET (05:20 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
